131885-65-9

Upstream product

• 288-32-4 1H-imidazole 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 611-06-3 2,4-dichloronitrobenzene 
• 350-46-9 4-Fluoronitrobenzene 
• 2301-25-9 1-(4-nitrophenyl)-1H-imidazole 
• 1635-61-6 5-chloro-2-nitroaniline 

Downstream Products

• 131886-22-1 6-chloro-N-(5-imidazol-1-yl-2-nitrophenyl)nicotinamide 
• 131885-79-5 4-(1H-imidazol-1-yl)benzene-1,2-diamine 

Relevant academic research and scientific papers

Synthesis and Catalytic Applications of Heterobimetallic Carbene Complexes Obtained via Sequential Metalation of Two Bisazolium Salts

A simple sequential metalation approach starting from the imidazolium/benzimidazolium salt 4(I)2 yielded the heterobimetallic RhIII/M (M = PdII, IrI, AuI, RuII) complexes [6]-[9]. Alternatively, a symmetrical 1,3-imidazolium substituted benzene was used for the preparation of the heterobimetallic M′/PdII (M′ = RhIII, IrIII) complexes [12] and [13]. The versatile stepwise approach used for the preparation of complexes [6]-[9] involved the deprotonation reaction of the bisazolium salt 4(I)2 in the presence of [RhCp?(Cl)2]2 to afford the monometallic complex [5]I featuring a chelating coordinated bidentate CNHC^Cphenyl ligand. Complex [5]I was reacted with Ag2O to give a nonisolated RhIII/AgI complex which in a subsequent transmetalation reaction yielded the heterobimetallic RhIII/M bis-NHC complexes (M = PdII [6], IrI [7], AuI [8], RuII [9]). Similarly, heterobimetallic M′/PdII bis-NHC complexes [12] (M′ = RhIII) and [13] (M′ = IrIII) have been prepared from a symmetrical bisazolium salt by generating first the monometallic M′ complexes followed by a transmetalation reaction of the in situ generated M′/AgI complexes with [Pd(dmba)(μ-Cl)]2. The RhIII/PdII complexes [6] and [12] and the IrIII/PdII complex [13] were used as catalysts for two orthogonal tandem reactions, namely, the Suzuki-Miyaura coupling/transfer hydrogenation and the Suzuki-Miyaura-coupling/α-alkylation of ketones. The catalytic activity of the heterobimetallic complexes was compared to mixtures of the related monometallic analogues [14]-[17], with the heterobimetallic complexes generally showing a higher catalytic activity. In addition, nBuOH was found to play a dual role as an alkylating and reducing agent in the Suzuki-Miyaura coupling/α-alkylation of ketones.

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

OLIGOHETEROAROMATIC LUMINISCENT ASSEMBLIES AS HIGH-AFFINITY DNA SEQUENCE-DIRECTED LIGANDS

The present invention provides a novel class of oligoheteroaromatic assemblies with luminescence characteristics and composition based on integrated polyheterocyclic polyamide oligomers of multiple nitrogen-containing heteroaromatic of the general formula (I) This novel class of compounds of the present invention is capable of binding to targeted DNA sequence in the minor groove, and thus is useful for genomics applications. In particular, the compounds of the invention binds to the DNA at a binding stoichiometry of 2: 1 ternary complexation with very high affinity and sequence selectivity.

Sulfonamide-based compounds as protein tyrosine kinase inhibitors

Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.

Benzimidazole, benzoxazole and benzothiazole compounds

A compound of formula (I): wherein: R1 represents halogen or a different group as defined in the description, Ra and Rb, which mnay be identical or different, represent hydrogen, alkyl, or hydroxy, X represents oxygen or sulphur or NR, R being H or alkyl,

A convenient copper-catalyzed direct animation of nitroarenes with 9-alkylhydroxylamines

O-Alkylhydroxylamines, particularly O-methylhydroxylamine, aminate nitroarenes in the presence of a strong base and a copper catalyst to give aminonitroarenes in good yields, ortho- or para-Animation with respect to the nitro group takes place, and in some cases the ortho-aminated product is preferentially obtained. With 3-substituted nitrobenzenes where the substituent has a lone pair of electrons, preferential amination occurs at the 2-position to give the sterically most congested 3c-f, 14 and 22g.

6-(1H-imidazol-1-yl)-7-nitro-2,3 (1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA- type non-NMDA receptor

A novel series of quinoxalinediones possessing imidazolyl and related heteroaromatic substituents was synthesized and evaluated for their activity to inhibit [3H]AMPA binding from rat whole brain. From the structure- activity relationships, it was found that the 1H-imidazol-1-yl moiety could function as a bioisostere for the cyano and nitro groups, and that 6-(1H- imidazol-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione (11) showed the most potent activity for the AMPA receptor. Compound 11 was evaluated for selectivity versus other excitatory amino acid receptors, and its action against AMPA at its receptor in the rat striatum was characterized. These data showed that compound 11 was a selective antagonist for the AMPA receptor with a K(i) value of 0.084 μM, being approximately equipotent with 2,3-dihydro-6-nitro- 7-sulfamoylbenzo(f)quinoxaline (3) (NBQX; K(i) = 0.060 μM). Compound 11 was also found to give protection against sound-induced seizure on DBA/2 mice at the minimum effective dose of 3 mg/kg ip (3; 10 mg/kg ip).

Cardiotonic Agents. Synthesis and Cardiovascular Properties of Novel 2-Arylbenzimidazoles and Azabenzimidazoles

Novel 2-arylbenzimidazoles and azabenzimidazoles were synthesized, and their inotropic action was evaluated.Changes in left ventricular pressure, dP/dt max, were measured as an index of cardiac contractility.The structural features that impart optimal inotropic activity are presented.The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers.To investigate the mechanism of action, the most potent compounds were tested for their calcium-sensitizing properties and their potential for the inhibition of phosphodiesterase.Two compounds, 1 and 41, showed interesting in vitro and oral activity without side effects.They have a more potent calcium-sensitizing effect than MCI-154 and are under further investigation.